ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
2024年5月2日 - 5:05AM
ADC Therapeutics SA (NYSE: ADCT) today announced that the Company
has made grants of options to purchase an aggregate of 147,600 of
the Company’s common shares to four new employees on May 1, 2024
(each, a “Grant”). The Grants were offered as material inducement
to the employees’ employment. The grants were approved by the
Compensation Committee of the Company’s Board of Directors pursuant
to the Company’s Inducement Plan to motivate and reward the
recipients to perform at the highest levels and contribute
significantly to the success of the Company. The Grants were made
in reliance on the employment inducement exemption under the NYSE’s
Listed Company Manual Rule 303A.08. The Company is issuing this
press release pursuant to Rule 303A.08. The Grants shall vest and
become exercisable 25% on the first anniversary of the grant date,
and 1/48th of the aggregate number of shares subject to the award
on each monthly anniversary of the grant date thereafter, such that
the entire award will be vested as of the fourth anniversary of the
grant date, subject to continued employment with the Company.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a
commercial-stage global leader and pioneer in the field of antibody
drug conjugates (ADCs). The Company is advancing its proprietary
ADC technology to transform the treatment paradigm for patients
with hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA
(loncastuximab tesirine-lpyl) received accelerated approval by the
FDA and conditional approval from the European Commission for the
treatment of relapsed or refractory diffuse large B-cell lymphoma
after two or more lines of systemic therapy. ZYNLONTA is also in
development in combination with other agents and in earlier lines
of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple
ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle),
Switzerland and has operations in London and New Jersey. For more
information, please visit https://www.adctherapeutics.com/ and
follow the Company on LinkedIn.
ZYNLONTA® is a registered trademark of ADC
Therapeutics SA.
CONTACT:
Investors and MediaNicole
RileyADC TherapeuticsNicole.Riley@adctherapeutics.com+1
862-926-9040
ADC Therapeutics (NYSE:ADCT)
過去 株価チャート
から 5 2024 まで 6 2024
ADC Therapeutics (NYSE:ADCT)
過去 株価チャート
から 6 2023 まで 6 2024